ORASURE TECHNOLOGIES INC OSUR
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
2/9
Piotroski F — financial health
6.76
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $115.0M | -$68.7M | $48.2M | -$53.2M | $340.8M |
| 2024 | $185.8M | -$19.5M | $79.4M | $23.6M | $410.3M |
| 2023 | $405.5M | $53.7M | $171.7M | $135.8M | $430.7M |
| 2022 | $387.5M | -$17.1M | $148.4M | -$54.0M | $364.4M |
| 2021 | $233.7M | -$23.0M | $117.6M | -$57.3M | $380.5M |
| 2020 | $171.7M | -$14.9M | $101.9M | -$20.9M | $398.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Kenny John P. | director | 2026-06-03 | Grant | 46,106 | — |
| McMahon Robert W. | director | 2026-06-03 | Grant | 46,106 | — |
| Marmora Lelio | director | 2026-06-03 | Grant | 46,106 | — |
| Gagliano Nancy J | director | 2026-06-03 | Grant | 46,106 | — |
| Bertrand John D. | director | 2026-06-03 | Grant | 46,106 | — |
| Boyd Steven Kyle | director | 2026-06-03 | Grant | 46,106 | — |
| Boyd Steven Kyle | director | 2026-05-14 | Buy | 25,000 | $2.99 |
| McMahon Robert W. | director | 2026-05-13 | Tax withheld | 22,888 | $3.02 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.76 (safe)
- Working capital / assets 0.551
- Retained earnings / assets -0.427
- EBIT / assets -0.179
- Equity / liabilities 5.467
Source: SEC EDGAR filings · CIK 0001116463 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.